RCM
LSBPW

Radcliffe Capital Management’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Radcliffe Capital Management’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-57,636
Closed -$2.42K – 245
2023
Q3 		$2.42K Sell
57,636
-42,264
-42% -$2.21K ﹤0.01% 450
2023
Q2 		$5.44K Hold
99,900
– – ﹤0.01% 493
2023
Q1 		$15.6K Buy
+99,900
New +$15.1K ﹤0.01% 463

Other funds holding LSBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
SLM
Snow Lake Management Menlo Park, California $90.7M AUM 72.65% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BP
BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Radcliffe Capital Management's LSBPW Position: Q4 2023 in Review

Radcliffe Capital Management sold out of LakeShore Biopharma Warrants (LSBPW) in Q4 2023, closing a stake of 57,636 shares — an estimated $2.42K sold.

Radcliffe Capital Management first reported a position in LSBPW in Q1 2023 and held it in 3 quarters. The position peaked at $15.6K in Q1 2023. 28 funds tracked by Wall St. Rank hold LSBPW as of Q4 2023.

  • Radcliffe Capital Management reported no remaining LakeShore Biopharma Warrants position as of Q4 2023 after selling out during the quarter.
  • Radcliffe Capital Management sold 57,636 LakeShore Biopharma Warrants shares in Q4 2023, an estimated $2.42K.
  • Radcliffe Capital Management first reported a position in LakeShore Biopharma Warrants in Q1 2023 and held it in 3 quarters.
  • Radcliffe Capital Management's LakeShore Biopharma Warrants position peaked at $15.6K in Q1 2023.
  • 28 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q4 2023.

Based on Radcliffe Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.